Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30933494 | 1.00 | PKM (0.32) | PKMGAA | |
| SCHEMBL2918852 | 0.81 | MEN1 (0.36) | — | |
| SCHEMBL30014250 | 0.79 | GABRA1 (0.34) | PKM | |
| SCHEMBL332293 | 0.79 | GAA (0.33) | PKMGAA | |
| SCHEMBL333557 | 0.79 | — | — | |
| SCHEMBL10717222 | 0.79 | GABRA1 (0.34) | PKM | |
| SCHEMBL489929 | 0.78 | RIPK1 (0.41) | — | |
| SCHEMBL1494587 | 0.76 | GAA (0.38) | PKMGAA | |
| SCHEMBL333545 | 0.74 | CSNK2A1 (0.40) | — | |
| SCHEMBL4034762 | 0.72 | TRPA1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503475-B2 | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-12-23 | — | — | US | disclosed |
| EP-4635944-A1 | 2-AZABICYCLO[3.1.1]HEPTANE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-10-22 | — | — | EP | disclosed |
| US-20250171402-A1 | Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors | UNIV NORTHWESTERN (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250100968-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES | OXFORD FINANCE LLC | 2025-03-27 | — | — | US | disclosed |
| US-12240815-B2 | Potent and selective human neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4486445-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES | Centessa Pharmaceuticals (UK) Limited (GB) | 2025-01-08 | — | — | EP | disclosed |
| CN-119156375-A | Bicyclic heterocyclic derivatives and related uses | 森特萨制药(英国)有限公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2024128305-A1 | 2-AZABICYCLO[3.1.1]HEPTANE COMPOUND | 第一三共株式会社 | 2024-06-20 | — | — | WO | disclosed |
| WO-2023167865-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES | OREXIA THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023167865-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES | OREXIA THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | WO | disclosed |
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| CN-116583502-A | Bicyclic-heterocyclic derivatives and their use as orexin-2 receptor agonists | 欧瑞夏治疗有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-4208444-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | Orexia Therapeutics Limited (GB) | 2023-07-12 | — | — | EP | disclosed |
| CN-115551832-A | Potent human neuronal nitric oxide synthase inhibitors | 西北大学 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022051596-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OREXIA THERAPEUTICS LIMITED (GB) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503475-B2 | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | HCRTR2, HCRTR1, CRHR2 | PKM 2409/4885GAA 1870/4885 |
| US-12240815-B2 | Potent and selective human neuronal nitric oxide synthase inhibitors | NOS2, NOS1, NOS3 | PKM 1858/4885GAA 998/4885 |
| US-20230271973-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR2 | PKM 2409/4885GAA 1870/4885 |
| US-20250100968-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES | HCRTR2, HCRTR1, CRHR1 | PKM 1460/4885GAA 1022/4885 |
| US-20250171402-A1 | Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors | NOS2, NOS1, NOS3 | PKM 1858/4885GAA 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.